Mundipharma: Cancer Pain trials

The registry lists 12 Cancer Pain studies with Mundipharma as lead sponsor. 1 are open to participants now and 4 have results posted.

Phase 2 1Phase 3 4Phase 4 4No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Real-world Study of the Effectiveness and Tolerability of Outpatient Titration of OxyContin for the Moderate and Severe Pain in Cancer PatientsNot yet recruitingNCT07869797
• An Interventional Study for Patient With Cancer Pain to Evaluate the Efficacy and Safety of OxyNorm® Compared to Morphine Sulfate Through the IV Continuous Infusion.CompletedNCT02660229Phase 4Results posted
• Determine the Safety and Efficacy of Oxy/Nal Tablets Compared to Oxy PR in Subjects With Cancer PainCompletedNCT01885182Phase 3Results posted
• PROspective Non-interventional Open laBEl Trial for TARGIN in Korean Patients With Cancer PainCompletedNCT01719757Phase 4Results posted
• Immediate-Release Oxycodone Capsules Study in Cancer PainCompletedNCT01675622Phase 3Results posted
• Safety and Effectiveness of Transdermal Buprenorphine in Cancer PainCompletedNCT04315831
• A Study to Evaluate Buprenorphine Transdermal Patch in Chinese Subjects With Moderate to Severe Chronic Cancer PainStatus unknownNCT03967327Phase 3
• A Study to Compare the Titration Efficacy and Safety of Control-released Oxycodone and Immediate-released Oxycodone in Patients With Moderate to Severe Cancer PainCompletedNCT03176199Phase 4
• Study Evaluating Safety and Tolerability of Oxycodone in Patients With Moderate to Severe Cancer PainCompletedNCT03176121Phase 4
• Effect of Good Pain Management (GPM) Ward Program on Moderate to Severe Cancer Pain PatientsStatus unknownNCT03155516Not applicable
• A Study to Assess the Safety and Tolerability of Oxycodone Hydrochloride 50mg/mL Administered as an InfusionTerminatedNCT00626600Phase 3
• A Study Comparing Oxycodone to Oxycodone/Naloxone in Moderate to Severe, Chronic Cancer PainCompletedNCT00513656Phase 2